Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113388 | 0.93 | NPC1 (0.50) | NPC1RAB9APOLBCYP2C9MMP13 | |
| SCHEMBL13668720 | 0.91 | NPC1 (0.48) | NPC1RAB9APOLBCYP2C9MMP13 | |
| SCHEMBL13266245 | 0.84 | CYP2C9 (0.37) | NPC1RAB9APOLBCYP2C9MMP13 | |
| SCHEMBL10227070 | 0.82 | NPC1 (0.55) | NPC1RAB9APOLBCYP2C9MMP13 | |
| SCHEMBL13082664 | 0.82 | PPARA (0.40) | NPC1RAB9APOLBCYP2C9ELANE | |
| SCHEMBL13082581 | 0.81 | MCL1 (0.40) | NPC1RAB9APOLBCYP2C9ELANE | |
| SCHEMBL13082580 | 0.81 | MCL1 (0.40) | NPC1RAB9APOLBCYP2C9ELANE | |
| SCHEMBL13181445 | 0.80 | NPC1 (0.44) | NPC1RAB9APOLBCYP2C9ELANE | |
| SCHEMBL12606798 | 0.79 | NPC1 (0.56) | NPC1RAB9APOLBCYP2C9ELANE | |
| SCHEMBL10227054 | 0.78 | PPARA (0.43) | NPC1RAB9APOLBCYP2C9ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| US-20090269645-A1 | POLYMER, POLYMER ELECTROLYTE AND FUEL CELL USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090253015-A1 | POLYARYLENE BLOCK COPOLYMER AND USE THEREOF | SUMITOMO CHEMICAL COMPANY ,LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090036632-A1 | Polyarylene and Process for Producing the Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | NPC1 1871/4885RAB9A 392/4885POLB 2820/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | NPC1 1945/4885RAB9A 206/4885POLB 3351/4885 |
| US-20090036632-A1 | Polyarylene and Process for Producing the Same | CYP1A1, CYP1B1, C1R | NPC1 1867/4885RAB9A 3021/4885POLB 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.